Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Exclusion Criteria

• •Clinically significant ocular disease
• •Retinal diseases that may progress during the study period
• •Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles
• •Previous glaucoma intraocular surgery
• •Refractive surgery in either eye
• •Ocular hyperemia score of moderate (+2) or severe (+3) at Qualification Visit #2
• •Ocular trauma
• •Ocular infection or inflammation
• •Any corneal disease that may confound assessment
• •Evidence of corneal deposits or cornea verticillata
• •Known hypersensitivity to any component of netarsudil ophthalmic solution 0.02%, ripasudil hydrochloride hydrate ophthalmic solution 0.4%, or to topical anesthetic.
• •Mean central corneal thickness \>620 um
• •Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g. keratoconus)
• •Cannot demonstrate proper delivery of the eye drop
• •Clinically significant systemic disease
• •Participation in any investigational study within 30 days prior to screening
• •Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.